Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study MONDAY, May 12, 2025 (HealthDay News) — A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...